We’re thrilled to share that Omnix Medical’s research, in collaboration with Dr. Heching, the Adult Cystic Fibrosis and Bronchiectasis Clinic Director at Beilinson-Rabin Medical Center, has been awarded the prestigious award for Outstanding Scientific Research at the 2024 North American Israeli Pulmonary Alliance (NAIPAC) Conference in Jerusalem.
The work, which summarizes a one-year study evaluating the in vitro antimicrobial activity of Omnix Medical’s novel antimicrobial peptide, OMN51, against Pseudomonas aeruginosa clinical isolates demonstrated potent and consistent efficacy across both sensitive, resistant and multidrug resistant strains, highlighting OMN51’s potential as a powerful new therapeutic candidate.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under Grant Agreement No 966627 (OMNIX MEDICAL).